The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 02, 2019
Filed:
Oct. 04, 2011
Nilanjana Banerjee, Armonk, NY (US);
Angel Janevski, New York, NY (US);
Sitharthan Kamalakaran, Pelham, NY (US);
Vinay Varadan, New York, NY (US);
Nevenka Dimitrova, Pelham Manor, NY (US);
Robert Lucito, East Meadow, NY (US);
Nilanjana Banerjee, Armonk, NY (US);
Angel Janevski, New York, NY (US);
Sitharthan Kamalakaran, Pelham, NY (US);
Vinay Varadan, New York, NY (US);
Nevenka Dimitrova, Pelham Manor, NY (US);
Robert Lucito, East Meadow, NY (US);
Koninklijke Philips N.V., Eindhoven, NL;
Abstract
The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10, FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.